Clinical trials
Lung Cancer, Non-Small Cell clinical trials
Below are recruiting lung cancer, non-small cell clinical trials, each written for real people, not researchers. We’re tracking 1,128 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05060796RecruitingEarly Phase 1
CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
GuangzhouAges 18–75 - NCT05061550RecruitingPhase 2
Targeted immune-plus-chemo treatment before and after lung surgery
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Little Rock, ArkansasAges 18–95 - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05085028RecruitingPhase 3
Lower-dose pembrolizumab for lung cancer after 6 months
This trial studies whether giving pembrolizumab less often can work just as well for advanced non-small cell lung cancer after you’ve already had 6 months of treatment and are still benefiting. It may help reduce how often you need treatment while keeping cancer control.
BournemouthAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05100069Recruiting
Survey about brigatinib for ALK-positive lung cancer
This trial is a survey study about how brigatinib is used for people with certain advanced lung cancer. It may help doctors understand real-world treatment patterns and experiences for ALK-positive non-small cell lung cancer.
TokyoAges Any age - NCT05104788RecruitingPhase 2
Icotinib plus chemotherapy before surgery for EGFR lung cancer
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
BeijingAges 18–75 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05122806Recruiting
Study of cancer biology in ALK-positive advanced lung cancer
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
Saint-Denis, La RéunionAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT05167487Recruiting
Study of treatment effects after chemotherapy and surgery for lung cancer
This trial looks at how lung tumors respond after chemotherapy given before surgery in people with stage IIIA non-small cell lung cancer (NSCLC). It may help doctors understand which past treatments lead to better results, since it uses medical records from approved clinical cases.
A Coruña, A CoruñaAges 18 years+ - NCT05168566RecruitingPhase 2
Sutetinib for lung cancer with a specific EGFR change
This Phase 2 study tests sutetinib capsules in people with advanced (locally advanced or metastatic) non-small cell lung cancer. It’s for tumors that have a specific, uncommon EGFR mutation, and aims to see how well the drug can control the cancer with limited prior chemotherapy.
Glendale, CaliforniaAges 18 years+ - NCT05172739RecruitingPhase 4
Opioid-free anesthesia during lung surgery for early lung cancer
This study tests whether an opioid-free pain/anesthesia plan during elective lung surgery can reduce surgical “stress” on the body and affect the immune system. You may be eligible if you have early-stage non-small cell lung cancer and are scheduled for a specific type of surgery (VATS lobectomy).
Heraklion, CreteAges 18–80 - NCT05198830RecruitingPhase 2
Adding TRC102 to standard chemoradiation for stage III lung cancer
This Phase 2 trial tests whether adding TRC102 to standard chemotherapy plus radiation can improve outcomes for people with stage III non-squamous, non-small cell lung cancer. It is designed for newly staged patients and aims to help the immune system work better while treating the tumor.
Buena Park, CaliforniaAges 18 years+ - NCT05198154Recruiting
Blood test to watch lung cancer risk after immunotherapy
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
Changsha, HunanAges 18 years+ - NCT05234307RecruitingPhase 1
Nivolumab plus PBF-1129 for advanced lung cancer
This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.
Columbus, OhioAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT05241028RecruitingPhase 2
Adjuvant ensartinib for ALK-positive lung cancer after surgery
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
Shijiazhuang, HebeiAges 18–75 - NCT05254184RecruitingPhase 1
Vaccine and immunotherapy for KRAS-mutated lung cancer
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Baltimore, MarylandAges 18–100 - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT05257967Recruiting
Testing spinal fluid in EGFR-mutant lung cancer with brain covering spread
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
Vancouver, British ColumbiaAges 18 years+ - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, non-small cell?
- Yes. Clin2 currently lists 1,128 recruiting lung cancer, non-small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, non-small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, non-small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.